Clinical Trial Update: 64Cu-LLP2A for Imaging Hematologic Malignancies [EARLY_Phase 1]

View source ↗

Summary

Phase 1 imaging trial evaluating 64Cu-LLP2A in hematologic malignancies is currently recruiting, targeting multiple myeloma and various lymphomas.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Follicular Lymphoma
• Low-grade Non-hodgkin Lymphoma
• Lymphoplasmacytic Lymphoma
• Marginal Zone Lymphoma
• Multiple Myeloma
• Small Lymphocytic Lymphoma

Drugs mentioned

• 64Cu-LLP2A (Copper-64 LLP2A)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Multiple Myeloma, Low-Grade Lymphoma | EARLY_Phase 1 | Status: RECRUITING